![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Posts
;
Chief Research Officer @etpisano looks to the future of mammography screening through the #TMIST4BC clinical trial. Learn more with @SusanGKomen 
@eaonc
.@skmaithel of @WinshipAtEmory is leading EA2197/OPT-IN, a #ClinicalTrial for patients with incidentally discovered stage 2-3 #GallbladderCancer. Find more information here: https://bit.ly/EA2197 #gicsm
The #ComboMATCH Study, led by researchers from @StanfordCancer, @MDAndersonNews, @PennCancer, & @NCItreatment, is testing new combinations of anti-#cancer drugs, based on the characteristics of patients’ tumors. Learn more: http://bit.ly/ComboMATCH #PrecisionMedicine
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
41
Active Clinical Trials
1,400
Participating Institutions
67
International Sites
21,000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
